THNR vs XPH

THNRCAmplify Weight Loss Drug & Treatment ETF

XPHBState Street SPDR S&P Pharmaceuticals ETF

In short

THNR The GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

XPH Most pharma funds are a mega-cap sandwich. XPH equal-weights instead, so a small-cap drugmaker gets roughly the same say as an industry giant, across about 60 names, for 0.35% a year.

Stated mandate

THNR The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

XPH The fund seeks to provide exposure to the pharmaceuticals segment of the S&P TMI.

Why people hold it

• THNR Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
• Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
• Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

• XPH Modified equal weighting with quarterly rebalances: the index trims what has run and keeps real room for small and mid-cap drugmakers, not just the household names.ssga.com
• At 0.35%, the cheapest sticker in its pharma peer group and well under the group median of 0.57% (PPH 0.36%, IHE 0.37%, PJP 0.57%, FTXH 0.60%).
• Pure pharma, not a health care grab bag: it draws only from the pharmaceuticals segment of the S&P Total Market Index. No insurers, hospitals or device makers.ssga.com
• Running since 2006 under a single index rulebook, with assets in the mid-size range and about 60 holdings behind it.

Worth knowing

• THNR The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
• A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
• One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

• XPH Equal weighting pulls the portfolio down the cap ladder, where trial results and FDA decisions can swing a single stock hard. Expect a bumpier ride than mega-cap pharma.ssga.com
• One industry, one country. Drug pricing rules and patent cliffs hit the whole basket at once.
• Moderately traded rather than a volume monster, so spreads can widen. Limit orders are the usual answer.

Full THNR profile⁠

Full XPH profile⁠